

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited (the “Hong Kong Stock Exchange”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Medcaptain Medical Technology Co., Ltd.
深圳麥科田生物醫療技術股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2041)

CHANGE OF REGISTERED CAPITAL AND AMENDMENTS TO THE ARTICLES OF ASSOCIATION

This announcement is made by Medcaptain Medical Technology Co., Ltd. (the “**Company**”) pursuant to Rule 13.51(1) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The 10th meeting of the second board of directors (the “**Board**”) of Medcaptain Medical Technology Co., Ltd. was held on the date of this announcement, which reviewed and approved the proposal on changing the registered capital and amending the Articles of Association of the Company. Given that the Company has completed the issuance of H shares and is listed on the Main Board of the Stock Exchange of Hong Kong Limited (the “**Listing**”), the Board approved to change its registered capital and amend the relevant provisions of its Articles of Association based on the H share issuance situation. The details are as follows:

I. Change in the Company’s Registered Capital

With the filing with the China Securities Regulatory Commission and the approval of the Hong Kong Stock Exchange, the 38,910,600 H shares issued by the Company were listed and traded on the Main Board of the Hong Kong Stock Exchange on September 7, 2026. The Company’s total share capital increased by 38,910,600 shares, from 499,716,086 shares to 538,626,686 shares, and its registered capital increased by RMB38,910,600, from RMB499,716,086 to RMB538,626,686.

II. Amendments to Certain Provisions of the Articles of Association

Based on the change in the Company’s registered capital and the H share issuance situation, the Board approved to amend relevant provisions of the Articles of Association as follows:

Original Articles of Association	Amended Articles of Association
Article 3 The Company completed the filing with the China Securities Regulatory Commission (hereinafter referred to as the “CSRC”) on February 13, 2026, and upon approval by The Stock Exchange of Hong Kong Limited (hereinafter referred to as the “Hong Kong Stock Exchange”), issued [•] overseas-listed shares (hereinafter referred to as the “H Shares”) under its initial public offering. The shareholders of the Company converted a total of [•] domestic unlisted shares of the Company held by them into H Shares. The aforementioned H Shares were listed on the Hong Kong Stock Exchange on [•]. 	Article 3 The Company completed the filing with the China Securities Regulatory Commission (hereinafter referred to as the “CSRC”) on February 13, 2026, and upon approval by The Stock Exchange of Hong Kong Limited (hereinafter referred to as the “Hong Kong Stock Exchange”), issued 38,910,600 overseas-listed shares (hereinafter referred to as the “H Shares”) under its initial public offering. The shareholders of the Company converted a total of 440,311,086 domestic unlisted shares of the Company held by them into H Shares. The aforementioned H Shares were listed on the Hong Kong Stock Exchange on September 7, 2026.
Article 6 The Company’s registered capital is RMB[•].	Article 6 The Company’s registered capital is RMB538,626,686.
Article 19 The total share capital of the Company is [•] shares, all of which are ordinary shares, comprising [•] domestic unlisted shares, representing [•]% of the total share capital of the Company; and [•] ordinary H shares, representing [•]% of the total share capital of the Company.	Article 19 The total share capital of the Company is 538,626,686 shares, all of which are ordinary shares, comprising 59,405,000 domestic unlisted shares, representing 11.03% of the total share capital of the Company; and 479,221,686 ordinary H shares, representing 88.97% of the total share capital of the Company.

Save for the abovementioned amendments to the Articles of Association, other articles thereof remain unchanged.

III. Other Information

Pursuant to the authorization from the first extraordinary general meeting of the shareholders of the Company in 2024, such amendments to the Articles of Association do not need to be submitted to the general meeting of the shareholders for further review and approval. The Board authorizes the Company to designate such persons as it deems appropriate to handle the relevant registration of changes and related filing procedures.

The full text of the amended Articles of Association has been published on the website of the Hong Kong Stock Exchange (www.hkexnews.hk) and the website of the Company (www.medcaptain.com).

By Order of the Board
Medcaptain Medical Technology Co., Ltd.
深圳麥科田生物醫療技術股份有限公司
Mr. LIU Jie
Chairman of the Board and executive director

Hong Kong, September 28, 2026

As at the date of this announcement, the Board comprises: (i) Mr. LIU Jie, Mr. ZHONG Yaoqi and Mr. YAN Renzhong as executive Directors, (ii) Ms. LI Hui, Mr. ZHANG Jiecheng and Dr. ZHOU Yi as non-executive Directors, and (iii) Dr. SHAO Liyang, Mr. ZHANG Hanbin and Mr. TAM Man Hong as independent non-executive Directors.